2023 annual financial data
TScan Therapeutics 2023 Net margin
Direct answer
Net margin was -423.86%.
Operating income was -93.46M USD and net income was -89.22M USD.
Operating cash flow was -61.36M USD.
Get free TScan Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 21.05M USD
- Operating income
- -93.46M USD
- Net income
- -89.22M USD
- Operating cash flow
- -61.36M USD